Canvas Wealth Advisors LLC Has $1.45 Million Position in The Clorox Company (NYSE:CLX)

Canvas Wealth Advisors LLC increased its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 178.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,171 shares of the company's stock after buying an additional 6,513 shares during the period. Canvas Wealth Advisors LLC's holdings in Clorox were worth $1,445,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CLX. Norges Bank bought a new position in shares of Clorox in the 4th quarter worth about $259,041,000. FMR LLC increased its holdings in Clorox by 75.4% in the fourth quarter. FMR LLC now owns 1,361,758 shares of the company's stock worth $221,163,000 after purchasing an additional 585,526 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Clorox by 549.8% during the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after buying an additional 459,203 shares in the last quarter. ExodusPoint Capital Management LP grew its position in shares of Clorox by 187.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock worth $113,508,000 after buying an additional 456,114 shares during the period. Finally, Man Group plc increased its stake in shares of Clorox by 154.6% in the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock valued at $92,655,000 after acquiring an additional 346,449 shares in the last quarter. 78.53% of the stock is owned by institutional investors.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The shares were bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Wells Fargo & Company dropped their price target on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Jefferies Financial Group reduced their price target on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday. UBS Group decreased their price target on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Barclays reduced their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $149.50.

Clorox Stock Performance

Shares of CLX stock opened at $118.03 on Friday. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The firm has a market cap of $14.55 billion, a price-to-earnings ratio of 21.19, a P/E/G ratio of 2.70 and a beta of 0.54. The Clorox Company has a 52 week low of $117.35 and a 52 week high of $171.37. The firm's 50-day simple moving average is $131.62 and its two-hundred day simple moving average is $145.61.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. During the same quarter in the previous year, the business earned $1.71 EPS. The company's revenue for the quarter was down 8.0% on a year-over-year basis. As a group, equities analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.